Ab Initio opens new R&D Facility at Macquarie Park

Ab Initio is pleased to announce it has opened a new R&D facility in Sydney’s Macquarie Park.
As part of its ongoing expansion, Ab Initio has moved into a three story building on Talevera road, which it has fitted out to provide state-of-the-art testing and R&D services to Australian and overseas companies developing innovative therapeutics.

The move will build capacity for the company and further support operations at its TGA licensed GMP manufacturing facility on the Royal Prince Alfred Campus in Camperdown.

The expansion into the Macquarie Park innovation district is strategic as it places company operations within the ‘Pill Hill’ region of Sydney, which is home to over 180 large international businesses. These include J&J, Sanofi, Novartis, MSD, Amgen, Biogen, Merck, AstraZeneca, Boehringer Ingelheim, and Astellas, along with many start-ups, small medium enterprises and Macquarie University’s main campus..The close proximity of these entities within Macquarie Park facilitates a unique cross-pollination of ideas and research-driven advancements.

Chief Operations Officer, Dr William Glover said “the move to Macquarie Park will enable us to build new relationships within this vibrant innovation district while continuing to expand and build on relationships with our existing partners. Ab Initio has grown rapidly over the past 2 years and the move to this new site will allow us to accomodate our current expansion plans”

Chief Scientific Officer Hui Xin Ong said “the expansion of Ab Initio onto this new site will provide us with significantly increased capacity for our clients and allow us to accelerate client projects bringing them into the clinic faster.”

To learn more about ab initio’s pharmaceutical product R&D services and GMP manufacturing capabilities you can click the link www.ab-initio-pharma.com